Loading...
Market
What will be Annexon Biosciences' net income status for fiscal year 2024?
3
Resolution / Starting Odds
Positive net income • 33%
Break-even • 33%
Negative net income • 33%
Annexon Biosciences' quarterly and annual financial reports
Story
Annexon Biosciences' ANX005 Meets Phase 3 Endpoint in GBS, Shares Surge Over 55%
Jun 4, 2024, 11:30 AM
Annexon Biosciences announced that its experimental drug, ANX005, met the primary endpoint in a Phase 3 trial for treating Guillain-Barré Syndrome (GBS). The trial showed a highly statistically significant 2.4-fold improvement in the GBS-DS endpoint at 8 weeks with a 30 mg/kg dose, compared to placebo (p=0.0058). However, the 75 mg/kg dose did not show statistical significance (p=0.5548). Following the announcement, Annexon's shares surged more than 31% before the bell, were up 55% in pre-market trading, and rose 48.0% pre-market. The company will discuss the Phase 3 data in a conference call and webcast on Tuesday, June 4, 2024, at 8:30 a.m. ET.
View original story
Similar markets
Less than $15 • 25%
$15 to $30 • 25%
$31 to $50 • 25%
More than $50 • 25%
Yes • 50%
No • 50%
Increase • 33%
Decrease • 33%
Remain stable • 34%
Regeneron • 50%
Mammoth Biosciences • 50%
Loss • 33%
Breakeven • 34%
Profit • 33%
Increase by over 20% • 33%
Increase by 10-20% • 33%
Increase by less than 10% • 34%
Less than 5% • 25%
5%-10% • 25%
10%-15% • 25%
More than 15% • 25%
Profitable • 25%
Break-even • 25%
Minor losses • 25%
Significant losses • 25%